WallStSmart

Chevron Corp (CVX)vsGilead Sciences Inc (GILD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Chevron Corp generates 531% more annual revenue ($185.73B vs $29.44B). GILD leads profitability with a 28.9% profit margin vs 5.9%. GILD appears more attractively valued with a PEG of 0.38. GILD earns a higher WallStSmart Score of 72/100 (B).

CVX

Buy

50

out of 100

Grade: C-

Growth: 2.7Profit: 5.0Value: 4.0Quality: 4.0
Piotroski: 2/9

GILD

Strong Buy

72

out of 100

Grade: B

Growth: 5.3Profit: 9.5Value: 8.7Quality: 5.5
Piotroski: 6/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CVXSignificantly Overvalued (-43.2%)

Margin of Safety

-43.2%

Fair Value

$127.43

Current Price

$181.62

$54.19 premium

UndervaluedFair: $127.43Overvalued
GILDUndervalued (+43.2%)

Margin of Safety

+43.2%

Fair Value

$236.08

Current Price

$131.33

$104.75 discount

UndervaluedFair: $236.08Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CVX2 strengths · Avg: 9.0/10
Market CapQuality
$360.80B10/10

Mega-cap, among the largest globally

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

GILD6 strengths · Avg: 9.3/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Return on EquityProfitability
40.7%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
37.4%10/10

Strong operational efficiency at 37.4%

Market CapQuality
$166.40B9/10

Large-cap with strong market position

Profit MarginProfitability
28.9%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
23.4%8/10

Earnings expanding 23.4% YoY

Areas to Watch

CVX4 concerns · Avg: 3.5/10
P/E RatioValuation
31.8x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
3.5%4/10

3.5% revenue growth

Return on EquityProfitability
7.2%3/10

ROE of 7.2% — below average capital efficiency

Profit MarginProfitability
5.9%3/10

5.9% margin — thin

GILD1 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Comparative Analysis Report

WallStSmart Research

Bull Case : CVX

The strongest argument for CVX centers on Market Cap, Price/Book. PEG of 1.11 suggests the stock is reasonably priced for its growth.

Bull Case : GILD

The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bear Case : CVX

The primary concerns for CVX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : GILD

The primary concerns for GILD are Revenue Growth.

Key Dynamics to Monitor

CVX carries more volatility with a beta of 0.50 — expect wider price swings.

GILD is growing revenue faster at 4.7% — sustainability is the question.

GILD generates stronger free cash flow (3.1B), providing more financial flexibility.

Monitor OIL & GAS INTEGRATED industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GILD scores higher overall (72/100 vs 50/100), backed by strong 28.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Chevron Corp

ENERGY · OIL & GAS INTEGRATED · USA

Chevron Corporation is an American multinational energy corporation. One of the successor companies of Standard Oil, it is headquartered in San Ramon, California, and active in more than 180 countries. Chevron is engaged in every aspect of the oil and natural gas industries, including hydrocarbon exploration and production; refining, marketing and transport; chemicals manufacturing and sales; and power generation.

Gilead Sciences Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Want to dig deeper into these stocks?